Full text - Abstract book [open access]
Conference Paper
SARS-CoV-2 specific neutralizing antibodies in vaccinated and unvaccinated HIV-positive individuals in the Dominican Republic
Estrella Vargas, Michelle M.
|
Gordo Febo, Wilfredo M.
|
Jabier Frías, Maridania
|
Salas, R.
|
Sánchez Morfe, Nelissa
|
Cuevas Martínez, Paula
|
Mueses Jiménez, Sayira P.
|
Ruiz De León, Ingrid C.
|
Lora Rodríguez, Héctor J.
|
Cepeda-Marte, Jenny L.
|
Paulino-Ramírez, Robert
| Fecha de publicación | Revista |
2022 |
Resumen
Occurrence of COVID infection in high burden HIV countries has been observed and associated to chronic infections and variants emergence. In the Dominican Republic it is estimated 1% of the population living with HIV. The aim of this study was to evaluate specific SARS-CoV-2 neutralizing antibodies in PLWHIV in a HIV Clinic, and to determine the clinical characteristics of reported COVID-19. Blood samples were collected after informed consent was signed for SARS-CoV-2 neutralizing antibodies detection. Data was collected from March 2020-October 2021. All participants completed a questionnaire. Samples were analyzed using IchromaTM II using a cut-off index (COI) for fluorescent interpretation. A total of 213 participants fulfil the study inclusion criteria. Mean age was 31 years old (SD 14). SARS-CoV-2 neutralizing antibodies were detected in 75% of participants. None experienced severe COVID-19. Vaccination status with at least one dose was reported in 71% of participants. The most common symptoms reported were anosmia 69% (n=65), dysgeusia 65% (n=61) and cough 60% (n=56). The most frequent comorbidity was arterial hypertension 61% (n=43), and diabetes mellitus 10% (n=7). A weak negative correlation was found between antibody detection and immune status (CD4 counts/HIV viral loads), rho=-0.218, p < 0.05. Knowing the most frequent clinical manifestations of people with SARS-CoV-2 and living with HIV helps us to offer a timely diagnosis and avoid future complications. Detection of specific neutralizing antibodies in immunosuppressed and/or not virally suppressed will facilitate immunological comprehension of vaccine campaigns (including boosters) and other preventive interventions.